HYMAN IP LAW
Biotechnology Patent and Licensing Services
Portfolio Evaluation and Opinion Work

Larry Hyman's patent portfolio evaluation and opinion work includes:

  -  preparing the opinion on Dendreon Corp.'s patent portfolio that supported the venture capital investment in its

     "ProvengeR" prostate cancer vaccine;

  -  preparing the due diligence review of patents and applications on Elixir Pharmaceutical's diabetes treatment

     composition and treatment regimens;
 

  -  evaluating the patent portfolio underlying Alimera Science's retinal disease treatment;

  -  preparing the opinion on Third Wave Technologies' patent portfolio on its "InvaderR" PCR labeling technology

  -  evaluating the patent portfolio held by a company seeking to market a diagnostic endoscope
;

  -  preparing the opinion on Novomer Inc.'s patent portfolio on a catalytic process for formulating plastics;

  -  evaluating a portfolio of patents on caspase inhibitors;

  -  preparing a freedom to operate opinion on a device modulating circadian rhythm;

  -  preparing a freedom to operate opinion on a nucleic-acid based vaccine; and,

  -  preparing a landscape review on microfluidic PCR devices.


HYMAN IP LAW
555 California Street, Suite 4925
San Francisco, CA 94109-1924
 
Phone: 415-440-3100
Fax:     415-440-3131
 
Email: lhyman (at) hymaniplaw.com

Web:  www.hymaniplaw.com

 

Home About Larry HymanIn the NewsServicesPatent ExperienceLicensing and Transactional ExperiencePortfolio Evaluation and Opinion WorkContact